ProCE Banner Activity

Combination Immunotherapy Plus Chemotherapy as First-line Therapy of Advanced NSCLC: Where Are We Now?

Clinical Thought
The combination of pembrolizumab plus carboplatin/pemetrexed for the first-line treatment of advanced NSCLC is currently under review by the FDA. In this commentary, I discuss my thoughts on the use of this regimen in patients with newly diagnosed advanced NSCLC.

Released: April 11, 2017

Expiration: April 10, 2018

No longer available for credit.

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Merck, and Pfizer and fees for non-CME/CE services from Ariad, Genentech/Roche, and Lilly.